Skip to main content
IMRN logo

Immuron Limited (IMRN) Stock Price & Analysis

Immuron Limited (IMRN) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $0.8663 (-0.52%), as of the Nov 18, 2026 trading session; market cap $6.99M.

Educational signal · not a buy or sell recommendation · How to read this

$0.8663 −$0.0045 (-0.52%) Market Cap $6.99M

Immuron Limited · IMRN · NASDAQ

Immuron Limited is an Australian biopharmaceutical company specializing in oral immunotherapeutics derived from polyclonal antibodies, targeting gut health and infectious diseases. The company commercializes products like Travelan and Protectyn, while advancing a pipeline including Phase III trials for traveler's diarrhea and anti-viral applications.

Price as of Nov 18, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Immuron (IMRN)

Weak
Business Quality Thin (37)
Financial Safety Okay (50)
Valuation Fair (73)
Growth Durability Growing (70)
Momentum Quiet (42)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but weak quality. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Quiet.

  • quarterly revenue A$4M (Q4 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 1 of the last 4 reports
  • Altman Z -6.25 · Piotroski F 4

Helping: an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IMRN (52 recorded, newest six shown)
RecordedScoreBand
23Weak
23Weak
23Weak
23Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.8663
Change on the day-0.52%
52-week range$0.6765 – $2.39
Market capitalisation$6.99M—
Shares traded on the day21.0K

Price & events

Other perspectives

Council score for Immuron (IMRN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Immuron (IMRN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Immuron Limited (IMRN) is listed on NASDAQ. It employs 7 people and is led by Steven George Lydeamore. In Q4 FY2026 it reported revenue of A$4M and net income of -A$2M. The market values it at $6.99M.

2 · Latest results

What do the latest results show for Immuron (IMRN)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of A$4M. Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026A$4M-A$2M-A$0.24 (diluted)
Q2 FY2026A$4M-A$2M-A$0.27 (diluted)
Q4 FY2025A$3M-A$3M-A$0.47 (diluted)
Q3 FY2025A$2M-A$1M-A$0.23 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Immuron (IMRN)?

Short answer

The MoonshotScore pillars rate an attractive price, durable growth as strengths. The distress and quality screens read Altman Z -6.25 · Piotroski F 4. Trailing ratios: ROE -38.3% · ROA -19.1% · current ratio 7.26.

Data-derived red flags

  • Listing risk — at $0.8663 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -6.25 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-38.3%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does Immuron compare with its peers?

Short answer

Immuron's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.48 Nov 18, 2026$884M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$29.68 Nov 18, 2026$993M64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Immuron (IMRN) — this page$0.8663$6.99M23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IMRN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IMRN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: IMRN Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for IMRN?

IMRN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is IMRN a good stock to buy?

Stock Expert AI does not rate IMRN buy, sell or hold. Immuron Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IMRN stock price today?

The last price recorded for Immuron Limited (IMRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for IMRN?

Immuron Limited (IMRN) holds a MoonshotScore in the low range. The global travel health market is projected to grow, with preventative measures being a key segment. Not financial advice.

How frequently does IMRN data refresh on this page?

IMRN's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IMRN's recent stock price performance?

Immuron Limited (IMRN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on polyclonal antibodies, a unique therapeutic approach. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IMRN overvalued or undervalued right now?

Immuron Limited (IMRN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research IMRN before investing?

Before investing in Immuron Limited (IMRN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding IMRN to a portfolio?

Key strength of Immuron Limited (IMRN): Specialized focus on polyclonal antibodies, a unique therapeutic approach. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.